Search research articles
Contact Us
Filters
Showing results (101-110 of 108) with videos related to
Page
of 11
Sort By:
You have reached the last page of results.
This site can display upto 108 results.
QJM : Monthly Journal of the Association of Physicians
|
July 16, 2024
Plasma NOTCH3 and the risk of cardiovascular recurrence in patients with ischemic stroke
R C S Seet, A M L Quek, O Teng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 6, 2024
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
I Melero, T Yau, Y-K Kang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 4, 2025
Autophagy activator AA-20 improves proteostasis and extends <i>Caenorhabditis elegans</i> lifespan
Ee Phie Tan, Nora Lyang, Saam Doroodian, et al.
The Journal of International Medical Research
|
August 9, 2002
Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron
Y K Kang, Y H Park, B Y Ryoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2020
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial<sup>☆</sup>
S H Park, D H Lim, T S Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 7, 2018
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
S T Kim, K C Banks, E Pectasides, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2018
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
G K Abou-Alfa, S Qin, B-Y Ryoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
L-T Chen, E Martinelli, A-L Cheng, et al.
Page
of 11
Search research articles
Search
Showing results (101-110 of 108) with videos related to
Sort By:
Page
of 11
You have reached the last page of results.
This site can display upto 108 results.
QJM : Monthly Journal of the Association of Physicians
|
July 16, 2024
Plasma NOTCH3 and the risk of cardiovascular recurrence in patients with ischemic stroke
R C S Seet, A M L Quek, O Teng, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
June 6, 2024
Nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma previously treated with sorafenib: 5-year results from CheckMate 040
I Melero, T Yau, Y-K Kang, et al.
Proceedings of the National Academy of Sciences of the United States of America
|
August 4, 2025
Autophagy activator AA-20 improves proteostasis and extends <i>Caenorhabditis elegans</i> lifespan
Ee Phie Tan, Nora Lyang, Saam Doroodian, et al.
The Journal of International Medical Research
|
August 9, 2002
Ramosetron for the prevention of cisplatin-induced acute emesis: a prospective randomized comparison with granisetron
Y K Kang, Y H Park, B Y Ryoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
December 5, 2020
A randomized phase III trial comparing adjuvant single-agent S1, S-1 with oxaliplatin, and postoperative chemoradiation with S-1 and oxaliplatin in patients with node-positive gastric cancer after D2 resection: the ARTIST 2 trial<sup>☆</sup>
S H Park, D H Lim, T S Sohn, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 7, 2018
Impact of genomic alterations on lapatinib treatment outcome and cell-free genomic landscape during HER2 therapy in HER2+ gastric cancer patients
S T Kim, K C Banks, E Pectasides, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
April 17, 2018
Phase III randomized study of second line ADI-PEG 20 plus best supportive care versus placebo plus best supportive care in patients with advanced hepatocellular carcinoma
G K Abou-Alfa, S Qin, B-Y Ryoo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
February 19, 2020
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with intermediate and advanced/relapsed hepatocellular carcinoma: a TOS-ESMO initiative endorsed by CSCO, ISMPO, JSMO, KSMO, MOS and SSO
L-T Chen, E Martinelli, A-L Cheng, et al.
Page
of 11